KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) Operating Margin (2016 - 2025)

Ionis Pharmaceuticals has reported Operating Margin over the past 17 years, most recently at 105.47% for Q4 2025.

  • Quarterly results put Operating Margin at 105.47% for Q4 2025, down 5656.0% from a year ago — trailing twelve months through Dec 2025 was 77.32% (down 994.0% YoY), and the annual figure for FY2025 was 40.45%, up 2693.0%.
  • Operating Margin for Q4 2025 was 105.47% at Ionis Pharmaceuticals, down from 102.21% in the prior quarter.
  • Over the last five years, Operating Margin for IONS hit a ceiling of 6990.8% in Q2 2025 and a floor of 136.95% in Q4 2022.
  • Median Operating Margin over the past 5 years was 64.21% (2021), compared with a mean of 300.24%.
  • Biggest five-year swings in Operating Margin: plummeted -50463bps in 2022 and later surged 702014bps in 2025.
  • Ionis Pharmaceuticals' Operating Margin stood at 367.67% in 2021, then crashed by -137bps to 136.95% in 2022, then skyrocketed by 99bps to 1.89% in 2023, then crashed by -2493bps to 48.91% in 2024, then crashed by -116bps to 105.47% in 2025.
  • The last three reported values for Operating Margin were 105.47% (Q4 2025), 102.21% (Q3 2025), and 6990.8% (Q2 2025) per Business Quant data.